CYTOKINETICS, INCORPORATED Financials Cytokinetics, Incorporated Deutsche Boerse AG
Equities
KK3A
US23282W6057
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.9 EUR | +2.67% |
|
+9.01% | -34.59% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 627.7 | 1,471 | 3,823 | 4,336 | 8,186 | 6,134 | - | - |
| Enterprise Value (EV) 1 | 531.8 | 1,142 | 3,495 | 4,163 | 8,179 | 6,100 | 5,718 | 5,754 |
| P/E ratio | -5.03 x | -10.5 x | -16.3 x | -10.6 x | -15.3 x | -12 x | -12 x | -19.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 23.4 x | 26.3 x | 54.3 x | 45.8 x | 1,087 x | 210 x | 81.7 x | 15.8 x |
| EV / Revenue | 19.8 x | 20.5 x | 49.6 x | 44 x | 1,086 x | 209 x | 76.2 x | 14.8 x |
| EV / EBITDA | -5.45 x | -12.4 x | -19 x | -13.1 x | -16.9 x | -13.5 x | -12.9 x | -29.9 x |
| EV / FCF | - | - | -18.3 x | -13.4 x | -19.7 x | -12.8 x | -11 x | -13.3 x |
| FCF Yield | - | - | -5.48% | -7.47% | -5.08% | -7.78% | -9.12% | -7.5% |
| Price to Book | -57.4 x | 13 x | 15.8 x | -40.3 x | -22 x | -13.4 x | -18.3 x | -82.3 x |
| Nbr of stocks (in thousands) | 59,161 | 70,779 | 83,883 | 94,631 | 98,054 | 116,204 | - | - |
| Reference price 2 | 10.61 | 20.78 | 45.58 | 45.82 | 83.49 | 52.79 | 52.79 | 52.79 |
| Announcement Date | 03/03/20 | 25/02/21 | 24/02/22 | 01/03/23 | 27/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 26.87 | 55.83 | 70.43 | 94.59 | 7.53 | 29.2 | 75.05 | 387.8 |
| EBITDA 1 | -97.57 | -92.11 | -184 | -318.4 | -484.3 | -450.3 | -442.5 | -192.4 |
| EBIT 1 | -98.87 | -93.94 | -186.3 | -324.2 | -496.2 | -468.5 | -477.4 | -266.5 |
| Operating Margin | -367.97% | -168.27% | -264.54% | -342.75% | -6,589.71% | -1,604.68% | -636.11% | -68.71% |
| Earnings before Tax (EBT) 1 | -121.7 | -127.3 | -215.3 | -389 | -526.2 | -489.6 | -507.2 | -330.3 |
| Net income 1 | -121.7 | -127.3 | -215.3 | -389 | -526.2 | -492 | -488.8 | -309.3 |
| Net margin | -452.93% | -228% | -305.72% | -411.21% | -6,988.63% | -1,685.13% | -651.35% | -79.76% |
| EPS 2 | -2.110 | -1.970 | -2.800 | -4.330 | -5.450 | -4.413 | -4.408 | -2.696 |
| Free Cash Flow 1 | - | - | -191.4 | -310.9 | -415.7 | -474.9 | -521.7 | -431.6 |
| FCF margin | - | - | -271.76% | -328.64% | -5,521.24% | -1,626.34% | -695.15% | -111.29% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 03/03/20 | 25/02/21 | 24/02/22 | 01/03/23 | 27/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.42 | 55.6 | 1.148 | 88.97 | 2.515 | 1.957 | 4.613 | 0.867 | 0.378 | 1.672 | 0.835 | 17.62 | 2.164 | 4.278 | 1.171 | 2.333 |
| EBITDA 1 | - | -20.97 | -76.52 | -9.467 | -107 | -125.4 | -122.6 | -120.2 | -120.4 | -121.1 | - | -103 | -113 | -102.8 | - | - |
| EBIT 1 | -62.72 | -21.7 | -77.86 | -10.87 | -108.4 | -127 | -124.5 | -122 | -122.3 | -127.4 | -126.2 | -112 | -113.6 | -111.3 | -119.9 | -118.5 |
| Operating Margin | -845.28% | -39.04% | -6,781.97% | -12.22% | -4,311.77% | -6,491.06% | -2,698.31% | -14,077.16% | -32,345.24% | -7,620.69% | -15,117.96% | -635.46% | -5,247.34% | -2,602.87% | -10,239.79% | -5,077.79% |
| Earnings before Tax (EBT) 1 | -80.19 | -30.57 | -89.44 | -19.82 | -142.3 | -137.4 | -131.3 | -128.6 | -129.4 | -136.9 | -135.6 | -114.5 | -116 | -118.8 | -113.9 | -118.2 |
| Net income 1 | -80.19 | -30.57 | -89.44 | -19.82 | -142.3 | -137.4 | -131.3 | -128.6 | -129.4 | -136.9 | -135.6 | -114.3 | -116.8 | -117.7 | -111.2 | -115.4 |
| Net margin | -1,080.73% | -54.98% | -7,791.38% | -22.28% | -5,658.45% | -7,019.93% | -2,846.07% | -14,837.02% | -34,238.62% | -8,187.56% | -16,244.67% | -648.39% | -5,396.74% | -2,751.84% | -9,493.28% | -4,947.42% |
| EPS 2 | - | -0.3600 | -1.050 | -0.2300 | -1.520 | -1.450 | -1.380 | -1.340 | -1.350 | -1.380 | -1.330 | -0.9767 | -1.110 | -1.054 | -1.138 | -1.063 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 06/08/20 | 24/02/22 | 04/05/22 | 04/08/22 | 03/11/22 | 01/03/23 | 04/05/23 | 03/08/23 | 02/11/23 | 27/02/24 | 08/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 95.9 | 328 | 329 | 173 | 7.45 | 33.9 | 417 | 381 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -191 | -311 | -416 | -475 | -522 | -432 |
| ROE (net income / shareholders' equity) | - | -112% | -121% | -572% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | -31.3% | -41.9% | -57.2% | -80.7% | -86.9% | -46.6% |
| Assets 1 | - | - | 687.6 | 928 | 919.5 | 609.3 | 562.7 | 664.1 |
| Book Value Per Share 2 | -0.1800 | 1.600 | 2.880 | -1.140 | -3.800 | -3.950 | -2.890 | -0.6400 |
| Cash Flow per Share 2 | - | - | - | -3.330 | -4.290 | -2.680 | -1.380 | - |
| Capex 1 | - | - | 48.9 | 11.3 | 1.42 | 1.04 | 13.5 | 29.5 |
| Capex / Sales | - | - | 69.39% | 11.98% | 18.8% | 3.55% | 18.04% | 7.6% |
| Announcement Date | 03/03/20 | 25/02/21 | 24/02/22 | 01/03/23 | 27/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
52.79
USD
Average target price
83.35
USD
Spread / Average Target
+57.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.94% | 125B | |
| +13.75% | 108B | |
| -7.52% | 24.21B | |
| +2.07% | 22.78B | |
| -10.79% | 17.96B | |
| -41.74% | 16.43B | |
| -14.14% | 16.37B | |
| +1.91% | 13.58B | |
| +27.84% | 11.66B |
- Stock Market
- Equities
- CYTK Stock
- KK3A Stock
- Financials Cytokinetics, Incorporated